References
- American Cancer Society. Cancer Facts and Figures, Available from: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. Accessed 8 January 2006
- Beck J R, Kattan M V, Miles B J. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152: 1894–1899
- Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (GNRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. J Steroid Biochem 1985; 123: 833–841
- Crawford E D, Blumenstein B A, Goodman P J, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66: 1039–1044
- Eisenberger M, Crawford E D, McLeod D, et al. A comparison of leuprolide and flutamide vs leuprolide alone in newly diagnosed stage D2 prostate cancer: Prognostic and therapeutic importance of the minimal disease subset. Proc Am Soc Clin Oncol 1992; 11: 201
- van Andel G, Kurth K H. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44: 209–214
- Hamilton J B. Role of testicular secretions as indicated by effects of castration in man and by studies of pathological conditions and short lifespan associated with maleness. Recent Prog Horm Res 1948; 3: 257–289
- Fonseca R S, Rajkumar V, White W L, et al. Anemia after orchiectomy. Am J Hematol 1998; 59: 230–233
- Weber J P, Walsh P C, Peters C A, Spivak J L. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991; 36: 190–194
- Eri L M, Tveter K J. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 1994; 152: 448–452
- Strum S B, Tismag G. Anemia of androgen deprivation (AAD) in patients receiving combination hormone blockade: Response to erythropoietin. Proc Am Soc Clin Oncol 1994; 13: 238
- Asbell S O, Leon S A, Tester W J, Brereton H D, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29: 243–248
- Ornstein D K, Beiser J A, Andriole G L. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83: 43–46
- Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, et al. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 2003; 23: 1757–1762
- Qian L, Hua L, Wu H, Sui Y, et al. Anemia in patients on combined androgen block therapy for prostate cancer. Asian J Androl 2004; 6: 383–384
- Choo R, Chander S, Danjoux C, Morton G, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients. Can J Urol 2005; 12: 2547–2552
- Strum S B, McDermed J E, Scholz M C, Johnson H, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933–941
- Oh W K. Anemia related to hormonal ablation therapy for prostate cancer. The Prostate Journal 2001; 3: 14–17
- Rodgers G, Cella D, Chanan-Khan A, Chesney C, et al. NCCN clinical practice guidelines in oncology. Cancer- and treatment-related anemia, Available from: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf Accessed January 26, 2007